<DOC>
	<DOCNO>NCT00352755</DOCNO>
	<brief_summary>This study prospectively evaluate multidisciplinary approach patient intraperitoneal carcinomatosis Washington University . Patients peritoneal carcinomatosis pseudomyxoma peritonei undergo debulking surgery peritonectomy placement adhesive barrier film follow repeat delayed intraperitoneal chemotherapy 5FU systemic oxaliplatin-based chemotherapy biweekly schedule . A retrospective review patient treat similar manner institution show good tolerance efficacy . This formal Phase II study plan determine safety , toxicity survival patient peritoneal carcinomatosis pseudomyxoma peritonei treat regimen .</brief_summary>
	<brief_title>A Phase II Study Surgical Debulking With Peritonectomy Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin Patients With Pseudomyxoma Peritonei Peritoneal Carcinomatosis</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Pseudomyxoma Peritonei</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Eligibility Criteria : Histological Diagnosis : Patients must histologically document pseudomyxoma peritonei peritoneal carcinomatosis colorectal/appendiceal small intestinal adenocarcinoma . Patients may prior chemotherapy . Age : Patients must great equal 18 year old . Because dose toxicity data currently available use oxaliplatin patient &lt; 18 year age , child exclude study , eligible pediatric Phase I singleagent trial , available . Performance Status : ECOG 02 . Life Expectancy : great 8 week . Recovery Intercurrent Illness : Patients must recover uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris cardiac arrhythmia . Hematological Status : Patients must adequate bone marrow function define absolute neutrophil count great equal 1,500/mm3 , platelet count great equal 100,000/mm3 hemoglobin great equal 8 g/dl . Hepatic Function : Total bilirubin must less equal institutional upper limit normal ( ULN ) . Transaminases ( SGOT and/or SGPT ) may 2.5 X ULN alkaline phosphatase less equal ULN , alkaline phosphatase may 4 x ULN transaminases less equal ULN . However , patient transaminase elevation great 1.5 x ULN alkaline phosphatase great 2.5 x ULN eligible study . Renal Function : Patients must adequate renal function define serum creatinine less equal 2.0 mg/dl creatinine clearance great equal 60 ml/min/1.73 m2 patient creatinine level 2.0 mg/dl . Sexually Active Patients : For sexually active patient , use adequate barrier contraception ( hormonal barrier method birth control ) require therapy , prior study entry duration study participation . Nonpregnant status determine woman childbearing potential . Pregnant nursing woman patient eligible . HIVPositive Patients : Patients receive antiretroviral therapy ( HAART ) HIV infection exclude study possible pharmacokinetic interaction . Appropriate study undertake patient receive HAART therapy , indicate . Informed Consent : After inform treatment involve , patient must give write consent . The patient serious medical psychiatric illness would prevent either give informed consent receipt treatment . Inclusion Women Minorities : Entry study open men woman racial ethnic subgroup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>